NeuroSense Therapeutics and NeuraLight have announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases, including amyotrophic lateral sclerosis (ALS).
NeuraLight uses proprietary computer vision and learning algorithms to extract coulometric markers from facial videos captured with a webcam. NeuroSense is conducting the phase IIB PARADIGM trial evaluating the efficacy of NeuroSense's lead combination drug candidate, PrimeC, in treating ALS.
The collaboration includes sharing and tracking patient data to advance the identification and use of ALS digital biomarkers in a study conducted by NeuraLight. This marks NeuraLight's first clinical trial.